{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T13:08:08Z","timestamp":1781874488708,"version":"3.54.5"},"reference-count":32,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T00:00:00Z","timestamp":1736640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tacrolimus is administered via a continuous or intermittent IV infusion to prevent acute graft versus host disease (aGvHD) in pediatric hematopoietic stem cell transplant (HSCT) recipients. Limited comparison data is available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The primary objective was to compare the proportion of therapeutic tacrolimus trough levels in the first 30 days post-stem cell infusion. Secondary outcomes were prevalence of aGvHD, intra-patient variability (IPV) and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Design<\/jats:title>\n                    <jats:p>This was a retrospective cohort study that included pediatric HSCT recipients between March 1, 2015 and October 31,2021 at BC Childrens Hospital. Adverse events were assessed using the Naranjo scoring tool.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 60 transplants in 59 patients were included; n\u2009=\u200936 intermittent IV and n\u2009=\u200924 continuous IV. Median proportion of blood levels (intermittent and continuous) within 8\u201312 ug\/L was 38% and 56%, respectively (p\u2009=\u20090.04). IPV was 33% and 31% and aGvHD was 39% and 38% in intermittent and continuous respectively. There was a higher proportion of adverse effects in the intermittent group with the exception of hypomagnesemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Continuous IV tacrolimus provided a higher proportion of levels within therapeutic range. Neither achieved therapeutic trough levels in more than 56% of transplants. However, there was large intra-patient variability in both groups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552241312925","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T03:03:50Z","timestamp":1736737430000},"page":"682-690","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Continuous versus intermittent tacrolimus for graft-versus-host disease prophylaxis in pediatric hematopoietic stem cell transplantation patients (Tic Tac)"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8753-1765","authenticated-orcid":false,"given":"Demi","family":"Asleson","sequence":"first","affiliation":[{"name":"Pharmacy Department, Childrens and Women's Health Centre of BC, Vancouver, Canada"},{"name":"Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxane","family":"Carr","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Childrens and Women's Health Centre of BC, Vancouver, Canada"},{"name":"Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Rozmus","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology\/Bone Marrow Transplant, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1977-8731","authenticated-orcid":false,"given":"Jennifer","family":"Kendrick","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Childrens and Women's Health Centre of BC, Vancouver, Canada"},{"name":"Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,1,12]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.01.004"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.276"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30256-X"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155214531609"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702472"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.11.679"},{"key":"e_1_3_3_8_2","first-page":"2062","article-title":"Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors","volume":"96","author":"Nash RA","year":"2000","unstructured":"Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062\u20132068.","journal-title":"Blood"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200059020-00021"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.02.005"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.12659\/AOT.904225"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.327"},{"key":"e_1_3_3_13_2","first-page":"1","article-title":"Prograf \u00ae product monograph page 1 of 82","author":"Pharm A","year":"2020","unstructured":"Pharm A. Prograf \u00ae product monograph page 1 of 82. Health Canada 2020: 1\u201382.","journal-title":"Health Canada"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.59"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25243"},{"key":"e_1_3_3_16_2","first-page":"1","article-title":"Comparison of intermittent intravenous tacrolimus to continuous tacrolimus in adult allogeneic stem cell transplant recipients","volume":"0","author":"Williams M","year":"2024","unstructured":"Williams M, Gul Z, Graff J, et al. Comparison of intermittent intravenous tacrolimus to continuous tacrolimus in adult allogeneic stem cell transplant recipients. J Oncol Pharm Pract 2024; 0: 1\u20137.","journal-title":"J Oncol Pharm Pract"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trre.2024.100878"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14052"},{"key":"e_1_3_3_19_2","first-page":"825","article-title":"1994 Consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka D;","year":"1995","unstructured":"Przepiorka D;, Weisdorf D;, Martin P, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transpl 1995; 15: 825\u2013828.","journal-title":"Bone Marrow Transpl"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220908948"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155215577809"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-020-04633-0"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.06.008"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.323"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14723"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002913"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-020-02986-8"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.16421221"},{"key":"e_1_3_3_30_2","first-page":"1","article-title":"Acute graft versus host disease","volume":"35","author":"Jacobsohn DA","year":"2007","unstructured":"Jacobsohn DA, Vogelsang GB. Acute graft versus host disease. Orphanet J Rare Dis 2007; 35: 1\u20139.","journal-title":"Orphanet J Rare Dis"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1716969"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.03.020"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704299"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241312925","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552241312925","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241312925","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T10:56:16Z","timestamp":1779274576000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552241312925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,12]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1177\/10781552241312925"],"URL":"https:\/\/doi.org\/10.1177\/10781552241312925","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,12]]}}}